University of Colorado Denver_ Anschutz Medical Campus

University of Colorado Denver_ Anschutz Medical Campus

13001 E. 17th Place

Campus Box C290

Aurora, CO 80045-2571

United States

The University of Colorado School of Medicine offers comprehensive, lifelong, interdisciplinary learning for health care professionals. With state-of-the art laboratories for discovery and innovation, a commitment to decreasing health disparities and increasing health equity, and faculty who provide world-class clinical care at Children’s Hospital Colorado and UCHealth University of Colorado Hospital, the CU School of Medicine is transforming the health care landscape.

Epigenetic Reprogramming of Macrophage Phagocytosis Using HDAC Inhibitors Against Pediatric Brain Tumors

Atypical Teratoid/Rhabdoid Tumor (AT/RT)

Mentor Name: Todd Hankinson & Siddhartha Mitra

Avishi Singh

University of Colorado Denver_ Anschutz Medical Campus

Dr. Michael Verneris, MD

University of Colorado Denver_ Anschutz Medical Campus

Advancing Biological Understanding of Adamantinomatous Craniopharyngioma for the Design of Clinical Trials

Brain Tumors

Understanding and Treating ACP: A New Hope for Children with a Rare and Devastating Brain Tumor

Dr. Todd Hankinson, MD

University of Colorado Denver_ Anschutz Medical Campus

A Cell Morphology Landscape of Pediatric Cancer Cell Lines

Neuroblastoma

Science has made impressive leaps in the ability to precisely measure what is unique about each childhood cancer patient, which has improved our ability to treat childhood cancers. However, there remain many patients for which treatments do not work and many more who suffer from life-long toxic side-effects. We therefore need to develop better and less toxic treatments for childhood cancer patients. One strategy that is growing in importance is the concept of high-throughput drug screening.

CDK12 Links Radiation Response to PARPi Sensitivity in Pediatric Glioma

Brain Tumors

High-grade gliomas (HGGs) are the leading cause of cancer-associated death in children, and new therapies are desperately needed for children with these tumors. The current standard-of-care treatment for HGG is radiation therapy. Radiation controls these tumors for a time, but they inevitably grow back. Understanding how HGG adapts to and recovers from radiation may allow us to interrupt that process, increasing the benefit of radiation and prolonging survival for children undergoing treatment.

A Novel Adjunctive LAT-Activating CART (ALA-CART) Cell Platform for the Treatment of Acute Leukemia

Leukemia, Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)

Immunotherapy has been promising for the treatment of cancers. Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized the treatment of pediatric relapsed B-cell acute lymphoblastic leukemia (ALL). CAR T-cell therapy involves collecting patient T cells and re-engineering them to specifically target cancer cells. Despite the initial success of CAR T-cell therapy, approximately 50% of ALL patients relapse within a year. Additionally, CAR T-cell therapy for acute myeloid leukemia (AML) has yet led to effective responses in patients.

Alex's Lemonade Stand Foundation for Childhood Cancer